The US Food and Drug
Administration (FDA) has
announced it has approved
Novartis’ Entresto (sacubitril/
valsartan) tablets for the treatment
of heart failure with studies
involving more than 8,000 patients
demonstrating it can reduce the
rate of cardiovascular death and
hospitalisation related to heart
failure.
The drug was part of the FDA’s
priority review program, with a fast
track designation.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jul 15
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.